Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › HORIZON

STRATIFYHF · Artificial intelligence-based decision support system for risk stratification and early detection of heart failure in primary and secondary care

HORIZONStatus: SIGNED1 June 202331 May 2027EU funding €4,495,438Call HORIZON-HLTH-2022-STAYHLTH-01-two-stage

Heart failure (HF) is a pandemic currently affecting up to 15 million people in Europe. It is a complex clinical syndrome presenting with impaired heart function and is associated with poor quality of life for patients and high healthcare costs. There is a high clinical demand for novel artificial intelligence (AI) tools which will facilitate risk stratification, early diagnosis, and disease progression assessment in HF. Such tools are essential to allow prompt initiation of evidence-based prevention and treatment strategies which will improve patient quality of life, reduce morbidity and mortality and the HF burden on healthcare. STRATIFYHF aims to develop, validate and implement the first AI-based, decision support system (DSS) for risk stratification, early diagnosis, and disease progression assessment in HF to accommodate both primary and secondary care clinical needs. The DSS will integrate patient-specific demographic and clinical data using existing and novel technologies and establish AI-based tools for risk stratification and HF prediction using machine learning. Additionally, a mobile app will be developed to empower patients to better manage their condition, and health care professionals to make informed decision in selection of evidence-based HF prevention and treatment strategies. Our multidisciplinary consortium, including three small-to-medium enterprises (SMEs) and two stakeholder organisations, will be guided by medical advice and regulatory and health technology experts to deliver the DSS as a medical class 2b device, reaching TRL 8 by the end of the project. STARTIFYHF will change the way in which HF is diagnosed today and thereby improve the quality and length of patients’ lives and lead to efficient and sustainable healthcare systems by reducing the number of HF-related hospital admissions and unnecessary referrals from primary to secondary care in Europe and beyond.

Consortium · 19 organisations

coordinator

ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO

RS · €892,500

associatedPartner

COVENTRY UNIVERSITY

UK

associatedPartner

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

UK

thirdParty

AZIENDA UNITA' SANITARIA LOCALE TOSCANA CENTRO

IT

participant

KLINIKUM DER UNIVERSITAET REGENSBURG

DE · €446,250

participant

UNIVERSITA DEGLI STUDI DI FIRENZE

IT · €436,250

participant

IDRYMA TECHNOLOGIAS KAI EREVNAS

EL · €438,750

associatedPartner

UNIVERSITY OF NEWCASTLE UPON TYNE

UK

participant

UDRUZENJE ZA SRCANU SLABOST SRBIJE

RS · €151,875

participant

SERVICIO MADRILENO DE SALUD

ES · €406,250

thirdParty

INSTITUT ZA KARDIOVASKULARNE BOLESTI VOJVODINE

RS

participant

MEDCON INTERNATIONAL BV

NL · €43,132

participant

BCN HEALTH ECONOMICS & OUTCOMES RESEARCH SL

ES · €346,500

participant

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

NL · €452,500

participant

UNIVERSITY OF NOVI SAD, FACULTY OF MEDICINE NOVI SAD

RS · €425,188

thirdParty

AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI

IT

associatedPartner

PKNM SOLUTIONS SARL

CH

participant

GPCARDIO BV

NL · €101,243

participant

UNIVERZA V LJUBLJANI

SI · €355,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.